News at a Glance

Jul 21, 2010 - Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) Supply Outlook

Jul 12, 2010 - Protalix BioTherapeutics Receives PDUFA Date for taliglucerase alfa

Jul 1, 2010 - Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV® (Velaglucerase Alfa) Through 69 Months

Jun 29, 2010 - Cerezyme® (imiglucerase for injection) Supply Update

Apr 27, 2010 - Protalix Submits Validation Data on Manufacturing Process to FDA

Apr 21, 2010 - Genzyme Provides Update on Product Supply and Consent Decree Terms

Mar 24, 2010 - Genzyme Announces FDA Enforcement Action Regarding Allston Plant

Feb 26, 2010 - Shire Announces FDA Approval of VPRIVTTM (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease

Feb 17, 2010 - Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year

Feb 11, 2010 - Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints

Feb 11, 2010 - Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium

Feb 2, 2010 - Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

Dec 9, 2009 - Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease

Dec 1, 2009 - Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment

Dec 1, 2009 - Genzyme Begins Shipping Newly Produced Cerezyme® from Allston Plant

Nov 4, 2009 - FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease

Oct 21, 2009 - Cerezyme® / Fabrazyme Update (See “Recovery of the Allston Plant)

Oct 20, 2009 - Genzyme announces enrollment in 2 global, multi-center, phase 3 trials of Genz-112638, potential new oral therapy for Gaucher type 1

Oct 15, 2009 - Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease

Sep 14, 2009 - Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease

Sep 8, 2009 - Shire Update on Velaglucerase Alpha

Sep 8, 2009 - FDA Grants Protalix Orphan Drug Designation for prGCD

Aug 25, 2009 - Protalix Receives FDA Fast Track Designation for prGCD

Aug 17, 2009 - U.S. Food and Drug Administration Approves Protalix's Treatment Protocol for prGCD

Aug 3, 2009 - Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA

Jul 16, 2009 - Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

Jul 14, 2009 - Protalix Holds Pre-NDA Meeting with FDA for prGCD

Jul 6, 2009 - Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease

Jul 6, 2009 - Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD